To accompany the upcoming EUnetHTA 2019 Assembly & Forum 0n 10-11th April in Amsterdam, a Welcome Guide has been developed to give participants and attendees a thorough overview of the event proceedings, practical information, and EUnetHTA's working activities. The guide is
EUnetHTA has developed documentation to address Conflict of Interest (COI) concerns and assist in the decision-making process relating to the assessment of individuals potentially involved in EUnetHTA JA3 activities. The Procedure Guidance for handling Declaration of Interest and Confidentiality Undertaking
EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
The day's agenda is now available for the upcoming 2019 EUnetHTA Forum on 11th April at the West-Indisch Huis in central Amsterdam. We are looking forward to hosting a collaborative, informative session of talks that both outline progress made in European
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
PTJA04 Final Project Plan – Sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues
Please see the below Final Project Plan of the Fourth Pharma Joint Assessment on 'sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues.' Timelines will change slightly due to the
Registration has now closed for the EUnetHTA 2019 Forum, held this year at the West-Indisch Huis in Amsterdam, the Netherlands, on 11 April 2019. Consisting of EUnetHTA Consortium partners, stakeholder groups, and other organisations involved in the activities of EUnetHTA JA3,
The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available.
The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available. We are pleased to announce that the collaborative rapid assessment on “C-reactive
OTCA16 Bioresorbable Stents for the Treatment of Cardiovascular Indications (coronary artery disease) Final Assessment Now Available.
We are pleased to announce that the collaborative rapid assessment, OTCA16, on “BIORESORBABLE STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS (CORONARY ARTERY DISEASE)” is now available. The health technology assessed is a device for percutaneous coronary intervention (PCI). The objective of
Final assessment report on MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer
Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint® This is the assessment of the relative effectiveness of MammaPrint® - Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast